TITLE

ESBATECH'S ANTIBODY FRAGMENT ENTERS CLINICAL DEVELOPMENT

PUB. DATE
June 2008
SOURCE
Worldwide Biotech;Jun2008, Vol. 20 Issue 6, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This arricle announces the initiation of Phase I clinical development of ESBATech AG's lead product development candidate, ESBA105, in ophthalmology. The study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. It is being conducted as a single and repeated dose escalation study in Switzerland.
ACCESSION #
32474190

 

Related Articles

  • PIII-76. Lobo, E.; Mitchell, M.; Kothare, P.; Johnson, J.; Van Lier, R.; Krull, J. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP79 

    Background: While several drugs are commercially available as the pamoate salts, information on the systemic exposure of pamoic acid (PA) from such drug products is not available in the literature. This study was conducted to determine the pharmacokinetics of PA from a marketed formulation,...

  • Animal Testing: OK or Not?  // New Moon Girls;Jul/Aug2012, Vol. 19 Issue 6, p10 

    The article presents views from several girls, 10 to 13 years old, whether animal testing of products must be conducted even if it is to evaluate their safety including one that suggests to start testing in simple animals and one which contends the concept as animals have the right to live.

  • Clinical pharmacology. Barber, H.E.; Petrie, J.C. // British Medical Journal (Clinical Research Edition);3/7/1981, Vol. 282 Issue 6266, p809 

    Focuses on the principles of drug elimination by the liver and the kidneys. Reason for the occurence of drug elimination in a constant rate; Influence of patient factor to drug clearance; Example of drug following zero-order elimination kinetics.

  • Factors affecting negative Common Drug Review recommendations in Canada.  // PharmacoEconomics & Outcomes News;3/3/2012, Issue 648, p2 

    The article reports on a study published in "PharmacoEconomics" which identified the association of clinical uncertainty and price considerations with negative Common Drug Review (CDR) recommendations in Canada.

  • Pregabalin Controlled-Release Pharmacokinetics in Healthy Volunteers: Analysis of Four Multiple-Dose Randomized Clinical Pharmacology Studies. Chew, Marci; Alvey, Christine; Plotka, Anna; Pitman, Verne; Alebic-Kolbah, Tanja; Scavone, Joseph; Bockbrader, Howard // Clinical Drug Investigation;Sep2014, Vol. 34 Issue 9, p627 

    Background: Pregabalin (Lyrica) is approved as an immediate-release (IR) formulation for administration twice (BID) or three times (TID) a day depending on indication. Once daily (QD) dosing may be appropriate for ease of clinical use and patient convenience. Objectives: The objectives of this...

  • Faster Pharmacokinetics. May, Mike // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p16 

    The article discusses the significant use of mass spectrometry (MS) in drug research's pharmacokinetics (PK) capabilities. It explains that MS methods were used in pharmacokinetic studies because it makes drug testing easy and more accurate. It notes that Agilent Technologies Inc.'s Jet Stream...

  • Bioavailability Study of Indomethacin Self-nanemulsifying Oral Formulation in Rats. Taha, Ehab. I.; Al-Suwayeh, Saleh A.; El-Badry, Mahmoud // Australian Journal of Basic & Applied Sciences;2009, Vol. 3 Issue 3, p2944 

    In the present study, a new self-nanoemulsified drug delivery formulation (SNEDDF) of indomethacin (IND) was tested in rats for its in vivo performance. Pharmacokinetic studies of IND SNEDDF was carried out after oral administration of the prepared formulation (capsules) and compared with that...

  • Blood donors on medication: Are deferral periods necessary? Stichtenoth, Dirk O.; Deicher, Helmuth R.; Frölich, Jürgen C. // European Journal of Clinical Pharmacology;Sep2001, Vol. 57 Issue 6/7, p433 

    Objectives: Drugs and their metabolites in transfused blood components may cause effects in the recipient. If the treated disorder is not to be regarded as an exclusion criterion from blood donation, donors on medication should be deferred for a period consistent with the drug's...

  • The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Lambert, David G. // Nature Reviews Drug Discovery;Aug2008, Vol. 7 Issue 8, p694 

    Identification of the enigmatic nociceptin/orphanin FQ peptide (N/OFQ) in 1995 represented the first successful use of reverse pharmacology and led to deorphanization of the N/OFQ receptor (NOP). Subsequently, the N/OFQ-NOP system has been implicated in a wide range of biological functions,...

Share

Read the Article

Courtesy of MICHIGAN ELIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics